FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766758038> ?p ?o ?g. }

• W2766758038 endingPage "325" @default.
• W2766758038 startingPage "316" @default.
• W2766758038 abstract "Abstract Purpose: The purpose of this study was to evaluate the safety and efficacy of ontuxizumab (MORAb-004), a monoclonal antibody that interferes with endosialin (tumor endothelial marker-1) function, in patients with chemorefractory metastatic colorectal cancer and to identify a responsive patient population based on biomarkers. Experimental Design: This was a randomized, double-blind, placebo-controlled, phase II study. Patients were randomly assigned in a 2:1 ratio to receive weekly intravenous ontuxizumab (8 mg/kg) or placebo plus best supportive care until progression or unacceptable toxicity. Tissue and blood biomarkers were evaluated for their ability to identify a patient population that was responsive to ontuxizumab. Results: A total of 126 patients were enrolled. No significant difference between the ontuxizumab and placebo groups was evident for the primary endpoint of progression-free survival (PFS), with a median PFS of 8.1 weeks in each group (HR, 1.13; 95% confidence interval, 0.76–1.67; P = 0.53). There were no significant differences between groups for overall survival (OS) or overall response rate (ORR). The most common treatment-emergent adverse events (TEAEs) in the ontuxizumab group (vs. the placebo group, respectively) were fatigue (53.7% vs. 47.5%), nausea (39.0% vs. 35.0%), decreased appetite (34.1% vs. 27.5%), and constipation (28.0% vs. 32.5%). The most common grade 3/4 TEAE in the ontuxizumab group versus placebo was back pain (11.0% vs. 0%). No single biomarker clearly identified patients responsive to ontuxizumab. Conclusions: No benefit with ontuxizumab monotherapy compared with placebo for clinical response parameters of PFS, OS, or ORR was demonstrated. Ontuxizumab was well tolerated. Clin Cancer Res; 24(2); 316–25. ©2017 AACR." @default.
• W2766758038 created "2017-11-10" @default.
• W2766758038 creator A5000669563 @default.
• W2766758038 creator A5013039829 @default.
• W2766758038 creator A5013142527 @default.
• W2766758038 creator A5016897894 @default.
• W2766758038 creator A5020942776 @default.
• W2766758038 creator A5026286947 @default.
• W2766758038 creator A5046311492 @default.
• W2766758038 creator A5050789569 @default.
• W2766758038 creator A5051338992 @default.
• W2766758038 creator A5057458005 @default.
• W2766758038 creator A5061373605 @default.
• W2766758038 creator A5068503288 @default.
• W2766758038 creator A5071328253 @default.
• W2766758038 creator A5082512772 @default.
• W2766758038 creator A5082669611 @default.
• W2766758038 date "2018-01-15" @default.
• W2766758038 modified "2023-09-25" @default.
• W2766758038 title "A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer" @default.
• W2766758038 cites W1953877425 @default.
• W2766758038 cites W1966530024 @default.
• W2766758038 cites W2005055996 @default.
• W2766758038 cites W2013010261 @default.
• W2766758038 cites W2019607817 @default.
• W2766758038 cites W2069506532 @default.
• W2766758038 cites W2074537181 @default.
• W2766758038 cites W2084054324 @default.
• W2766758038 cites W2086361694 @default.
• W2766758038 cites W2087666053 @default.
• W2766758038 cites W2117013761 @default.
• W2766758038 cites W2122999961 @default.
• W2766758038 cites W2125447919 @default.
• W2766758038 cites W2130261717 @default.
• W2766758038 cites W2130939988 @default.
• W2766758038 cites W2131314830 @default.
• W2766758038 cites W2138814678 @default.
• W2766758038 cites W2147297736 @default.
• W2766758038 cites W2147834058 @default.
• W2766758038 cites W2154881868 @default.
• W2766758038 cites W2157769714 @default.
• W2766758038 cites W2166700998 @default.
• W2766758038 cites W2217398072 @default.
• W2766758038 cites W2330814896 @default.
• W2766758038 cites W2416129203 @default.
• W2766758038 cites W2481715484 @default.
• W2766758038 cites W2533236332 @default.
• W2766758038 cites W2554782885 @default.
• W2766758038 cites W2606786998 @default.
• W2766758038 doi "https://doi.org/10.1158/1078-0432.ccr-17-1558" @default.
• W2766758038 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29084918" @default.
• W2766758038 hasPublicationYear "2018" @default.
• W2766758038 type Work @default.
• W2766758038 sameAs 2766758038 @default.
• W2766758038 citedByCount "13" @default.
• W2766758038 countsByYear W27667580382018 @default.
• W2766758038 countsByYear W27667580382019 @default.
• W2766758038 countsByYear W27667580382020 @default.
• W2766758038 countsByYear W27667580382021 @default.
• W2766758038 countsByYear W27667580382022 @default.
• W2766758038 countsByYear W27667580382023 @default.
• W2766758038 crossrefType "journal-article" @default.
• W2766758038 hasAuthorship W2766758038A5000669563 @default.
• W2766758038 hasAuthorship W2766758038A5013039829 @default.
• W2766758038 hasAuthorship W2766758038A5013142527 @default.
• W2766758038 hasAuthorship W2766758038A5016897894 @default.
• W2766758038 hasAuthorship W2766758038A5020942776 @default.
• W2766758038 hasAuthorship W2766758038A5026286947 @default.
• W2766758038 hasAuthorship W2766758038A5046311492 @default.
• W2766758038 hasAuthorship W2766758038A5050789569 @default.
• W2766758038 hasAuthorship W2766758038A5051338992 @default.
• W2766758038 hasAuthorship W2766758038A5057458005 @default.
• W2766758038 hasAuthorship W2766758038A5061373605 @default.
• W2766758038 hasAuthorship W2766758038A5068503288 @default.
• W2766758038 hasAuthorship W2766758038A5071328253 @default.
• W2766758038 hasAuthorship W2766758038A5082512772 @default.
• W2766758038 hasAuthorship W2766758038A5082669611 @default.
• W2766758038 hasBestOaLocation W27667580381 @default.
• W2766758038 hasConcept C121608353 @default.
• W2766758038 hasConcept C126322002 @default.
• W2766758038 hasConcept C141071460 @default.
• W2766758038 hasConcept C142724271 @default.
• W2766758038 hasConcept C143998085 @default.
• W2766758038 hasConcept C168563851 @default.
• W2766758038 hasConcept C197934379 @default.
• W2766758038 hasConcept C203092338 @default.
• W2766758038 hasConcept C204787440 @default.
• W2766758038 hasConcept C27081682 @default.
• W2766758038 hasConcept C2780580376 @default.
• W2766758038 hasConcept C2781112942 @default.
• W2766758038 hasConcept C2908647359 @default.
• W2766758038 hasConcept C31760486 @default.
• W2766758038 hasConcept C526805850 @default.
• W2766758038 hasConcept C535046627 @default.
• W2766758038 hasConcept C71924100 @default.
• W2766758038 hasConcept C90924648 @default.
• W2766758038 hasConcept C99454951 @default.
• W2766758038 hasConceptScore W2766758038C121608353 @default.

• next